Background
Methods
Search strategy
Inclusion and exclusion criteria
Methodological quality appraisal
Classification | Score | Description |
---|---|---|
Randomization | ||
Inappropriate | 0 | Semi-randomized or quasi-randomized trials |
Unclear | 1 | Randomized trials without describing methods for generating random sequences |
Appropriate | 2 | Random sequences produced by a computer or a random number table |
Allocation concealment | ||
Inappropriate | 0 | Regular grouping |
Unclear | 1 | Only use of a random number table or other random assignment scheme |
Appropriate | 2 | A method for assigning sequences without prediction |
Blinding | ||
Inappropriate | 0 | Use of double blindness without an appropriate method |
Unclear | 1 | Only mention of double blindness |
Appropriate | 2 | A description of the specific and appropriate method of double blindness |
Withdrawals or dropouts | ||
No | 0 | No description of withdrawal or dropouts |
Yes | 1 | A description of withdrawal or dropouts |
Statistical analysis
Results
Included studies
Author | Year | Country | Score | Treatment | TAPB_n (M/F) | TAPB_age# (years) | QLB_n (M/F) | QLB_age# (years) | Quality | Outcomes |
---|---|---|---|---|---|---|---|---|---|---|
Baytar | 2019 | Turkey | 4 | TAPB vs QLB | 53 (11/42) | 48.12 ± 12.42 | 54 (15/39) | 46.42 ± 16.57 | HQ | b f g |
Yousef | 2018 | Egypt | 5 | TAPB vs QLB | 30 (0/30) | 50.70 ± 6.8 | 30 (0/30) | 56.5 ± 6.97 | HQ | a b c d e f |
Kumar | 2018 | India | 4 | TAPB vs QLB | 35 (15/20) | 38.34 ± 11.59 | 35 (15/19) | 39.20 ± 11.64 | HQ | a b d f |
Öksüz | 2017 | Turkey | 3 | TAPB vs QLB | 25 (21/4) | 3.02 ± 1.82 | 25 (21/4) | 3.13 ± 0.20 | LQ | e f |
Blanco | 2016 | Arab | 3 | TAPB vs QLB | 38 (0/38) | NA | 38 (0/38) | NA | LQ | a |
Verma | 2019 | India | 6 | TAPB vs QLB | 30 (0/30) | 28 ± 3 | 30 (0/30) | 30 ± 3 | HQ | b d f |
Ipek | 2019 | Turkey | 3 | TAPB vs QLB | 29 (19/10) | 4.16 ± 2.55 | 35 (28/7) | 3.89 ± 3.26 | LQ | e f g |
Shan | 2019 | China | 3 | TAPB vs QLB | 30 (0/30) | 30 ± 3 | 30 (0/30) | 29 ± 6 | LQ | c f |
Deng | 2019 | China | 6 | TAPB vs QLB | 34 (12/22) | 53.5 ± 10.6 | 34 (14/20) | 51.1 ± 13.8 | HQ | b c f |
Fu | 2019 | China | 4 | TAPB vs QLB | 30 (NA) | 71.8 ± 5.8 | 30 (NA) | 72.2 ± 6.9 | HQ | b f |
Han | 2017 | China | 4 | TAPB vs QLB | 38 (24/14) | 27.8 ± 3.9 | 39 (20/19) | 26.3 ± 3.2 | HQ | b c f |
He | 2018 | China | 2 | TAPB vs QLB | 36 (20/16) | 67.3 ± 2.3 | 36 (19/17) | 67.7 ± 2.1 | LQ | e f |
Li G | 2018 | China | 5 | TAPB vs QLB | 40 (0/40) | 31 ± 4 | 40 (0/40) | 30 ± 5 | HQ | b c f |
Li N | 2019 | China | 3 | TAPB vs QLB | 30 (0/30) | 42.10 ± 5.26 | 30 (0/30) | 41.07 ± 4.75 | LQ | b e f |
Ma | 2019 | China | 3 | TAPB vs QLB | 30 (17/13) | 55. 2 ± 4. 4 | 30 (16/14) | 53.1 ± 4.6 | LQ | e |
Ren | 2018 | China | 3 | TAPB vs QLB | 82 (44/38) | 45.7 ± 15.2 | 78 (40/38) | 46.3 ± 15.1 | LQ | b c |
Xia | 2018 | China | 4 | TAPB vs QLB | 30 (15/15) | 48 ± 8 | 30 (12/18) | 46 ± 11 | HQ | f |
Yang | 2019 | China | 3 | TAPB vs QLB | 30 (0/30) | NA | 30 (0/30) | NA | LQ | a b |
Yang | 2019 | China | 5 | TAPB vs QLB | 30 (0/30) | 38.5 ± 14.8 | 30 (0/30) | 43.9 ± 15.04 | HQ | b c e f |
Ye | 2019 | China | 4 | TAPB vs QLB | 28 (12/16) | 48.9 ± 2.1 | 30 (14/16) | 50.3 ± 2.8 | HQ | c f |
Zhu | 2019 | China | 3 | TAPB vs QLB | 39 (20/19) | 68.8 ± 3.4 | 39 (18/21) | 69.1 ± 3.2 | LQ | e f |
Zhu | 2018 | China | 3 | TAPB vs QLB | 30 (0/30) | 52 ± 6 | 30 (0/30) | 51 ± 7 | LQ | b e f |
Overall meta-analysis
Outcomes | WMD/RR (95%CI) | P | I2 |
---|---|---|---|
Morphine consumption (mg) | |||
Overall | 3.893 (2.053, 5.733) | < 0.001 | 72.7 |
Operation types | |||
Abdominal surgery | 2.400 (1.825, 2.975) | < 0.001 | NA |
Pelvic surgery | 4.731 (2.634, 6.829) | < 0.001 | 44.5 |
Quality | |||
High-quality | 3.205 (1.283, 5.127) | 0.001 | 76.2 |
Low-quality | 6.443 (0.098, 12.788) | 0.047 | 72.2 |
Fentanyl consumption (μg) | |||
Overall | 23.815 (15.521, 32.109) | < 0.001 | 96.0 |
Operation types | |||
Abdominal surgery | 14.077 (7.412, 20.742) | < 0.001 | 92.3 |
Pelvic surgery | 34.808 (14.079, 55.537) | 0.001 | 96.5 |
Quality | |||
High-quality | 26.576 (13.594, 39.558) | < 0.001 | 96.9 |
Low-quality | 16.264 (7.527, 25.000) | < 0.001 | 73.3 |
Operative time | |||
Overall | 0.324 (−0.805, 1.454) | 0.573 | 0.0 |
Duration of anesthesia (min) | |||
Overall | -2.139 (−14.423, 10.146) | 0.733 | 80.8 |
VAS score at 24 h postoperatively | |||
Overall | 0.459 (0.118, 0.801) | 0.008 | 94.8 |
Operation types | |||
Abdominal surgery | 0.224 (−0.033, 0.480) | 0.088 | 80.1 |
Pelvic surgery | 0.671 (0.103, 1.240) | 0.021 | 95.4 |
Quality | |||
High-quality | 0.576 (0.048, 1.104) | 0.032 | 96.3 |
Low-quality | 0.218 (−0.019, 0.455) | 0.071 | 66.1 |
Duration of postoperative analgesia | |||
Overall | -21.882 (−59.774, 16.010) | 0.258 | 100.0 |
Operation types | |||
Abdominal surgery | -3.400 (−4.038, −2.762) | < 0.001 | NA |
Pelvic surgery | −31.125 (−78.851, 16.600) | 0.201 | 100.0 |
Number of patients requiring analgesia postoperatively | |||
Overall | 2.618 (2.040, 3.361) | < 0.001 | 13.2 |
Adverse reactions | |||
Dizziness | |||
Overall | 2.691 (1.653, 4.382) | < 0.001 | 0.0 |
Nausea and vomiting | |||
Overall | 1.918 (0.805, 4.571) | 0.141 | 50.9 |
Quality | |||
High-quality | 4.100 (1.932, 8.699) | < 0.001 | 0.0 |
Low-quality | 0.417 (0.054, 3.239) | 0.403 | 70.9 |